# AZD9056 Relative Bioavailability Study

> **NCT00908934** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 24 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** AZD9056 formulation Phase III 50 mg (T)
- **DRUG:** AZD9056 formulation Phase IIb 50 mg (R)
- **DRUG:** AZD9056 formulation Phase III 200 mg (T)
- **DRUG:** AZD9056 formulation Phase IIb 200mg (R)

## Key facts

- **NCT ID:** NCT00908934
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** —
- **Final completion:** 2009-07
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2009-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00908934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00908934, "AZD9056 Relative Bioavailability Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00908934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*